Inicio・Lista de Acciones・Arcus Biosciences Inc

Arcus Biosciences Inc

Abierto

SectorSanidad

28.81 4.42

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

27.39

Máximo

28.58

Métricas clave
By Trading Economics
Ingresos	-22M -128M
Ventas	-16M 17M
BPA	-1.02
Margen de beneficios	-752.941
Empleados	601
EBITDA	-42M -123M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+39.86% upside

Dividendos
By Acuity
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	229M 3.5B
Apertura anterior	24.39
Cierre anterior	28.81

Noticias sobre sentimiento de mercado

By Acuity

79%

21%

307 / 340 Clasificación en Healthcare

Arcus Biosciences Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 ago 2026, 19:36 UTC

Arcus Biosciences shares are lower today, reflecting broader market dynamics and geopolitical developments impacting investor sentiment. Earlier, shares peaked before declining.

31 jul 2026, 23:16 UTC

Arcus Biosciences Inc. shares are lower in after-market hours, continuing a trend of declining prices and remaining below the 20-day moving average.

30 jul 2026, 18:03 UTC

Arcus Biosciences Inc gains today, supported by a broader market uptick despite geopolitical tensions and inflation concerns. Shares pulled back from earlier session highs.

29 jul 2026, 19:56 UTC

Macro Event

Arcus Biosciences shares are lower amid broader market pressures from steady interest rates and rising crude oil prices, marking five consecutive sessions of decline.

28 jul 2026, 20:06 UTC

Arcus Biosciences Inc shares are lower today, reflecting broader market trends and declines in Asian markets, including significant losses in the Nikkei 225 Index.

27 jul 2026, 21:01 UTC

Arcus Biosciences Inc shares declined in after-market hours, continuing a downward trend over the last four sessions. No specific news was identified to explain the move.

24 jul 2026, 19:06 UTC

News

Arcus Biosciences has signed a clinical supply agreement with AVEO to evaluate casdatifan with tivozanib. Shares are trading lower, reflecting unusual weakness.

22 jul 2026, 20:13 UTC

Arcus Biosciences shares are higher in after-market hours. Broader market volatility is influenced by rising crude oil prices and geopolitical tensions.

21 jul 2026, 19:36 UTC

Arcus Biosciences shares are higher today, supported by overall market strength and positive sentiment in the biotechnology sector. The stock has advanced notably since Monday.

20 jul 2026, 18:06 UTC

News

H.C. Wainwright raised Arcus Biosciences' price target to $45 from $32, maintaining a Buy rating. Shares are higher today following the analyst's upgrade.

Comparación entre iguales

Cambio de precio

Arcus Biosciences Inc previsión

Precio Objetivo

By TipRanks

39.86% repunte

Estimación a 12 Meses

Media 38.63 USD 39.86%

Máximo 47 USD

Mínimo 22 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arcus Biosciences Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

Comprar

Mantener

Vender

De acuerdo con 9 analistas que ofrecen calificaciones bursátiles a para Arcus Biosciences Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

307 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.